Afghanistan

Population 2018 37 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>70 (45–100)</td>
<td>189 (122–270)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.32 (0.12–0.64)</td>
<td>0.87 (0.31–1.7)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence**</td>
<td>2.5 (1–4.7)</td>
<td>6.8 (2.8–13)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>11 (6.4–16)</td>
<td>29 (17–44)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.098 (0.036–0.19)</td>
<td>0.26 (0.1–0.52)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

<table>
<thead>
<tr>
<th>New cases</th>
<th>3% (1.4–5.3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously treated cases</td>
<td>12% (11–14)</td>
</tr>
</tbody>
</table>

TB case notifications, 2018

- % tested with rapid diagnostics at time of diagnosis 24%
- % with known HIV status 53%
- % pulmonary 71%
- % bacteriologically confirmed** 64%
- % children aged 0–14 years 21%
- % women 46%
- % men 33%

Total cases notified 48 800

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 69% (48–110)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018 16% (8–26)

Patients with known HIV status who are HIV-positive
- on antiretroviral therapy 7 <1%

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**
  - New cases 49%
  - Previously treated cases 95%

Laboratory-confirmed cases* MDR/RR-TB: 452, XDR-TB: 8

Patients started on treatment** MDR/RR-TB: 319, XDR-TB: 8

MDR/RR-TB cases tested for resistance to second-line drugs 253

Treatment success rate and cohort size

| New and relapse cases registered in 2017 | 91% | 46 640 |
| Previously treated cases, excluding relapse, registered in 2017 | 42% | 766 |
| HIV-positive TB cases registered in 2017 | 26% | 7 |
| MDR/RR-TB cases started on second-line treatment in 2016 | 62% | 153 |
| XDR-TB cases started on second-line treatment in 2016 | 82% | 153 |

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 95% (88–100)

TB financing, 2019

National TB budget (US$ millions) 17

Funding source: 3% domestic, 76% international, 21% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-12 Data: www.who.int/tb/data